Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Jianya ZHOU"'
Publikováno v:
Chinese Journal of Lung Cancer, Vol 27, Iss 8, Pp 593-604 (2024)
Lung cancer accounts for the highest proportion of cancer deaths in the world and poses a great threat to human health. About 30% to 40% of non-small cell lung cancer (NSCLC) is caused by point mutations, exon insertion and exon deletion of the epide
Externí odkaz:
https://doaj.org/article/131b95cb5c614b5fb7213230833882e2
Autor:
Jingjing Qu, Yuekang Li, Binggen Wu, Qian Shen, Lijun Chen, Wenjia Sun, Bo Wang, Lixiong Ying, Li Wu, Hong Zhou, Jianya Zhou, Jianying Zhou
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
The role of CD161+CD127+CD8+ T cells in non-small cell lung cancer (NSCLC) patients with diabetes remains unexplored. This study determined the prevalence, phenotype, and function of CD8+ T cell subsets in NSCLC with diabetes. We recruited NSCLC pati
Externí odkaz:
https://doaj.org/article/de02811caa2f4908bcd4631e6583885b
Publikováno v:
The Clinical Respiratory Journal, Vol 18, Iss 11, Pp n/a-n/a (2024)
ABSTRACT Background The incidence of small cell lung cancer (SCLC) among Asian patients is on the rise. Nevertheless, there remains a deficiency in precise prognostic models tailored to the specific needs of this patient population. It is imperative
Externí odkaz:
https://doaj.org/article/c9a0229f5dc64128a795fa80cae52bf3
Autor:
Fengqi Qiu, Peishan Jiang, Guiheng Zhang, Jie An, Kexin Ruan, Xiaowen Lyu, Jianya Zhou, Wanqiang Sheng
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract The antitumor efficacy of adoptively transferred T cells is limited by their poor persistence, in part due to exhaustion, but the underlying mechanisms and potential interventions remain underexplored. Here, we show that targeting histone de
Externí odkaz:
https://doaj.org/article/f0039109b23f4b06be07a63165120d6a
Autor:
Jingjing Qu, Binggen Wu, Lijun Chen, Zuoshi Wen, Liangjie Fang, Jing Zheng, Qian Shen, Jianfu Heng, Jianya Zhou, Jianying Zhou
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-16 (2024)
Abstract Background Mucosal-associated invariant T (MAIT) cells have been reported to regulate tumor immunity. However, the immune characteristics of MAIT cells in non-small cell lung cancer (NSCLC) and their correlation with the treatment efficacy o
Externí odkaz:
https://doaj.org/article/fd94651871714e86ad5c2ee7727bd109
Autor:
Jing Zheng, Tao Wang, Yunpeng Yang, Jie Huang, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Huijie Wang, Shundong Cang, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Giovanni Selvaggi, Yang Wang, Shanshan Xiao, Qian Wang, Zhilin Shen, Jianya Zhou, Jianying Zhou, Li Zhang
Publikováno v:
Cancer Communications, Vol 44, Iss 4, Pp 455-468 (2024)
Abstract Background The initial phase II stuty (NCT03215693) demonstrated that ensartinib has shown clinical activity in patients with advanced crizotinib‐refractory, anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC).
Externí odkaz:
https://doaj.org/article/dcd1b31af767472781f48f4856ca4755
Autor:
Cuihong Cai BS Med, Qian Shen MM, Jingjing Shao MD, Jingjing Qu MD, Shuangshuang Zhou MD, Jianya Zhou MD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 23 (2024)
There are no standard third-line or beyond treatments for patients with driver mutation-positive advanced lung adenocarcinoma (LUAD). Anlotinib was approved as a third-line multitarget drug in China in 2018. Limited data are available regarding the e
Externí odkaz:
https://doaj.org/article/430018f861eb4dd081f9e0eb9d8392f5
Autor:
Yongfeng Yu, Wen Dong, Yanxia Shi, Rong Wu, Qitao Yu, Feng Ye, Chengzhi Zhou, Xiaorong Dong, Xingya Li, Yongsheng Li, Zhen Li, Lin Wu, Yueyin Pan, Hong Shen, Dehua Wu, Zhongyuan Xu, Jinsheng Wu, Nong Xu, Yanru Qin, Aimin Zang, Jingdong Zhang, Jianya Zhou, Xiaotao Zhang, Yanqiu Zhao, Fugen Li, Huizhen Wang, Qi Liu, Zhenyong Han, Jin Li, Shun Lu
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: MET overexpression represents the most MET aberration in advanced non-small-cell lung cancer (NSCLC). However, except MET exon 14 ( MET ex14) skipping mutation was recognized as a clinical biomarker, the role of MET overexpression as a pr
Externí odkaz:
https://doaj.org/article/8250df8367a343a395e6e10c30dba4a2
Autor:
Tao Yuan, Chenming Zeng, Jiawei Liu, Chenxi Zhao, Fujing Ge, Yuekang Li, Meijia Qian, Jiamin Du, Weihua Wang, Yonghao Li, Yue Liu, Xiaoyang Dai, Jianya Zhou, Xueqin Chen, Shenglin Ma, Hong Zhu, Qiaojun He, Bo Yang
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-16 (2024)
Abstract Non-small cell lung cancer (NSCLC) ranks as one of the leading causes of cancer-related deaths worldwide. Despite the prominence and effectiveness of kinase-target therapies in NSCLC treatment, these drugs are suitable for and beneficial to
Externí odkaz:
https://doaj.org/article/f3833baff01f4f81b61eb42015e934f8
Autor:
Wenjia Sun, Fengqi Qiu, Jing Zheng, Liangjie Fang, Jingjing Qu, Shumeng Zhang, Nan Jiang, Jianying Zhou, Xun Zeng, Jianya Zhou
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-13 (2024)
Abstract Immune checkpoint inhibitors have transformed the treatment landscape of non-small cell lung cancer (NSCLC). However, accurately identifying patients who will benefit from immunotherapy remains a challenge. This study aimed to discover poten
Externí odkaz:
https://doaj.org/article/82c84b58a68f4d70a576d70d69db71c5